Clinical Practice Is Ahead Of Clinical Trials With Technology Use: EMR VS. ePRO

Client login

Home / Knowledge Centre /

Clinical Technologies / Clinical Practice Is Ahead Of Clinical Trials With Technology Use: EMR VS. ePRO

Case study

Back

Clinical Practice Is Ahead Of Clinical Trials With Technology Use: EMR VS. ePRO

This insightful piece highlights the advantages that both Electronic Medical Records (EMR) and an electronic Patient Reported Outcome (ePRO) systems provide in today’s clinical practice. However, clinical research has been a late adopter of ePRO systems. Learn about the multitude of benefits an ePRO system can provide.

You’ll discover these benefits and many more:

Cost-savings associated ePRO
Improved data quality
Reduction in patient / site burden

View Resource

Almac Clinical Technologies

Almac Clinical Technologies is here to help the biopharmaceutical industry bring new therapies to those in need by empowering clinical trial sponsors to proactively manage sites, patients, and clinical trial supplies through our industry-leading Interactive Response Technology (IRT) and expert consultancy.

Almac Clinical Technologies is uniquely positioned to unlock new efficiencies in the clinical supply chain and to help achieve greater predictability in your projects and programs.

Our professionals are dedicated to delivering high-quality Interactive Response Technology (IRT) solutions, dependable professional services, and reliable customer service. Our expertise, energy, and commitment have earned us a reputation as a trusted ally in the drug development process.

Learn More

You may also be interested in

Technical Sheet

Almac Clinical Technologies Biostatistics Group

Whitepaper

Master Protocols: Implementing effective treatment adaptations in the randomisation

Jennifer Ross

Stay up-to-date with the latest from Almac

Join our mailing list

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies

Download here instantly

Almac Clinical Technologies Biostatistics Group

Master Protocols: Implementing effective treatment adaptations in the randomisation